&Partners’s Corcept Therapeutics CORT Stock Holding History

&Partners’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-5,526	Closed	-$459K	–	2296
2025 Q3	$459K	Buy	5,526 +937	+20%	+$67.8K	﹤0.01%	1506
2025 Q2	$339K	Sell	4,589 -1,596	-26%	-$116K	﹤0.01%	1564
2025 Q1	$338K	Sell	6,185 -840	-12%	-$51.1K	﹤0.01%	1342
2024 Q4	$361K	Sell	7,025 -369	-5%	-$19.3K	﹤0.01%	1236
2024 Q3	$280K	Buy	+7,394	New	+$263K	0.01%	1134

Other funds holding CORT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

&Partners's CORT Position: Q4 2025 in Review

&Partners sold out of Corcept Therapeutics (CORT) in Q4 2025, closing a stake of 5,526 shares — an estimated $459K sold.

&Partners first reported a position in CORT in Q3 2024 and held it in 5 quarters. The position peaked at $459K in Q3 2025. 389 funds tracked by Wall St. Rank hold CORT as of Q4 2025.

&Partners reported no remaining Corcept Therapeutics position as of Q4 2025 after selling out during the quarter.
&Partners sold 5,526 Corcept Therapeutics shares in Q4 2025, an estimated $459K.
&Partners first reported a position in Corcept Therapeutics in Q3 2024 and held it in 5 quarters.
&Partners's Corcept Therapeutics position peaked at $459K in Q3 2025.
389 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q4 2025.

Based on &Partners's 13F filing for Q4 2025, filed 17 Feb 2026.